Britton Boras
Pfizer (United States)(US)Université Bourgogne Franche-Comté(FR)PRX Research
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer-related Molecular Pathways, SARS-CoV-2 and COVID-19 Research, Computational Drug Discovery Methods, Receptor Mechanisms and Signaling
Most-Cited Works
- → An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19(2021)1,855 cited
- → Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19(2021)288 cited
- → Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor(2021)172 cited
- → Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19(2020)159 cited
- → Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans(2022)113 cited
- → Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer(2021)112 cited
- → Nanoparticles for Improved Local Retention after Intra-Articular Injection into the Knee Joint(2012)82 cited
- → A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19(2024)61 cited
- → A Computational Modeling and Simulation Approach to Investigate Mechanisms of Subcellular cAMP Compartmentation(2016)49 cited
- → Discovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model(2024)42 cited